# colorectal cancer - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 47275
- Completion tokens: 19572
- Reasoning tokens: 0
- Total tokens: 66847
- API requests reported: 4
- Elapsed seconds: 89.01
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 4/5; original repeat 4; model vendor: DeepSeek

---
# Multidimensional Interpretation of Prognostic Transcriptomic Features in Colorectal Cancer (Overall Survival)

## 1. Overall Biological Interpretation

The prognostic transcriptomic signature comprises 100 unique genes (54 risk-associated, HR > 1; 46 protective-associated, HR < 1) from colorectal tumor tissue, with 71 genes passing FDR ≤ 0.05 and 8 passing FDR ≤ 0.01. The strongest signals (INHBB, SCARA3, MIR31HG, ZEB1-AS1, DCBLD2, TPM4) are risk-associated, while the strongest protective signals (ATP23, NDUFA9, SLC35G1) point toward mitochondrial/energy metabolism.

The dominant biological themes are: (1) **TGF-β/BMP signaling and mesenchymal/EMT programs** (INHBB, ZEB1-AS1, TPM4, ITGBL1, DCBLD2), (2) **mitochondrial function and metabolic remodeling** (protective: ATP23, NDUFA9, ATP5B, ATP5G1, CS, COA3, TIMM13, OGDHL; risk: SLC2A3, ACSS2-associated metabolism), (3) **extracellular matrix remodeling and adhesion** (ADAMTS18, ITGBL1, DCBLD2, NT5E, SCEL), (4) **growth factor signaling and survival pathways** (AKT3, FGF19, ABL2, GADD45B), and (5) **loss of intestinal differentiation markers** (protective: CDX2, CDX1, LGALS4, LGALS9, MYB).

The directionality is coherent: tumors with worse survival show upregulation of mesenchymal/EMT and growth-promoting programs, while better survival is associated with preservation of intestinal epithelial differentiation and intact mitochondrial oxidative metabolism.

## 2. Core Biological Programs

### Program 1: TGF-β Superfamily Signaling and EMT/Mesenchymal Program
- **Direction**: Risk-associated (poor OS)
- **Supporting genes**: INHBB (HR=1.433, FDR=0.001093), ZEB1-AS1 (HR=1.372, FDR=0.008647), TPM4 (HR=1.364, FDR=0.00891), DCBLD2 (HR=1.408, FDR=0.008647), ITGBL1 (HR=1.299, FDR=0.03061), PTPN14 (HR=1.362, FDR=0.02501)
- **Pathway**: TGF-beta signaling pathway (KEGG hsa04350); EMT (Hallmark)
- **Explanation**: INHBB encodes the activin/inhibin βB subunit of TGF-β superfamily ligands and has been specifically associated with poor prognosis and malignant phenotypes in colorectal cancer (Europe PMC 41992239). ZEB1-AS1 is a long non-coding RNA antisense to ZEB1, a master EMT transcription factor. TPM4 encodes tropomyosin 4, an actin-binding protein upregulated in mesenchymal states. DCBLD2 is a transmembrane protein linked to tumor invasion. ITGBL1 is an integrin-beta-like protein associated with metastasis. The co-occurrence of multiple independently significant genes converging on TGF-β/EMT biology constitutes a coherent poor-prognosis program.
- **Evidence strength**: Moderate-strong. Supported by multiple genes with FDR < 0.05 and literature (INHBB specifically in CRC). **Limitation**: This is pathway-level inference from individual gene HRs; no formal GSEA or pathway enrichment statistic was computed on this cohort.

### Program 2: Mitochondrial Oxidative Metabolism (Protective)
- **Direction**: Protective-associated (better OS)
- **Supporting genes**: ATP23 (HR=0.6885, FDR=0.006636), NDUFA9 (HR=0.6886, FDR=0.008647), ATP5B (HR=0.7483, FDR=0.05931), ATP5G1 (HR=0.7471, FDR=0.05194), CS (HR=0.7545, FDR=0.03875), COA3 (HR=0.7437, FDR=0.04336), TIMM13 (HR=0.7509, FDR=0.03938), OGDHL (HR=0.6858, FDR=0.07443)
- **Pathway**: Oxidative phosphorylation (KEGG hsa00190); Citrate cycle (TCA cycle) (KEGG hsa00020)
- **Explanation**: Multiple subunits of respiratory chain complexes and TCA cycle enzymes are protective. NDUFA9 (Complex I), ATP5B/ATP5G1 (Complex V), CS (citrate synthase), and assembly factors ATP23 and COA3 all point to preservation of mitochondrial oxidative metabolism. OGDHL (oxoglutarate dehydrogenase-like) is a TCA enzyme. This pattern suggests that tumors retaining oxidative mitochondrial function have better prognosis, consistent with the metabolic shift hypothesis where aggressive tumors rely more on aerobic glycolysis.
- **Evidence strength**: Moderate. Multiple independent genes with consistent protective direction. **Limitation**: ATP23's function is primarily mitochondrial protease/chaperone (literature: prohibitins interact genetically with Atp23); some genes (ATP5B, ATP5G1) have FDR slightly above 0.05.

### Program 3: Intestinal Differentiation and Epithelial Identity (Protective)
- **Direction**: Protective-associated (better OS)
- **Supporting genes**: CDX2 (HR=0.7478, FDR=0.0355), CDX1 (HR=0.7809, FDR=0.05735), LGALS4 (HR=0.7712, FDR=0.05123), LGALS9 (HR=0.7533, FDR=0.04204), MYB (HR=0.7706, FDR=0.01924), PRR15L (HR=0.8008, FDR=0.03939)
- **Pathway**: Intestinal epithelial differentiation; Wnt signaling modulation
- **Explanation**: CDX2 is the master intestinal transcription factor; its loss is a well-established marker of poor differentiation and worse prognosis in colorectal cancer. CDX2 suppresses Wnt/β-catenin signaling via GSK-3β and Axin2 transactivation (PubMed 30631044). LGALS4 (galectin-4) and LGALS9 are intestinal epithelial markers. MYB is a transcription factor involved in intestinal homeostasis. The protective direction of these differentiation markers is biologically coherent: loss of intestinal identity is associated with aggressive, dedifferentiated tumors.
- **Evidence strength**: Moderate-strong for CDX2 (well-established literature); moderate for the group. **Limitation**: CDX1 and LGALS4 have FDR slightly above 0.05.

### Program 4: Growth Factor Signaling and Survival Pathways (Risk)
- **Direction**: Risk-associated (poor OS)
- **Supporting genes**: AKT3 (HR=1.318, FDR=0.03875), FGF19 (HR=1.291, FDR=0.05123), ABL2 (HR=1.301, FDR=0.02757), GADD45B (HR=1.324, FDR=0.063), SLC2A3/GLUT3 (HR=1.281, FDR=0.07217)
- **Pathway**: PI3K-Akt signaling pathway (KEGG hsa04151); FGF signaling
- **Explanation**: AKT3 is a key PI3K/Akt pathway isoform promoting survival and proliferation. FGF19 is a growth factor implicated in gastrointestinal cancers. ABL2 (Arg) is a non-receptor tyrosine kinase involved in invasion. SLC2A3 (GLUT3) supports glucose uptake, consistent with glycolytic metabolism in aggressive tumors. GADD45B is a stress-response gene that can promote survival in certain contexts.
- **Evidence strength**: Moderate for AKT3 and ABL2 (FDR < 0.05); weaker for FGF19 and SLC2A3 (FDR 0.051–0.072). **Limitation**: The pathway is broad and these genes also participate in other programs; the "melanoma" and "gastric cancer" KEGG hits in the retrieved batch are not directly applicable to CRC without further analysis.

### Program 5: Extracellular Matrix Remodeling and Adhesion (Risk)
- **Direction**: Risk-associated (poor OS)
- **Supporting genes**: ADAMTS18 (HR=1.263, FDR=0.04681), ITGBL1 (HR=1.299, FDR=0.03061), NT5E/CD73 (HR=1.313, FDR=0.03939), SCEL (HR=1.254, FDR=0.03939), MAP1B (HR=1.327, FDR=0.0472), BACE1 (HR=1.329, FDR=0.04664)
- **Pathway**: ECM-receptor interaction (KEGG hsa04512); focal adhesion
- **Explanation**: ADAMTS18 is a metalloproteinase involved in ECM degradation. ITGBL1 is associated with integrin signaling. NT5E (CD73) is a well-known immunosuppressive ectoenzyme whose high expression correlates with poor prognosis across multiple cancers (PubMed 36480312). SCEL (sciellin) is a cell envelope protein. MAP1B is a microtubule-associated protein involved in cell motility. This ECM/adhesion program supports invasion and metastasis.
- **Evidence strength**: Moderate. Multiple genes with FDR < 0.05. **Limitation**: These genes also participate in other processes; the retrieved STRING/GO batch did not return a strong ECM-specific enrichment signal.

## 3. Key Genes and Interaction Modules

### 1. INHBB (Risk, HR=1.433, FDR=0.001093)
- **Statistical direction**: Strongest risk-associated gene in the dataset.
- **Biological role**: Encodes activin/inhibin βB; TGF-β superfamily signaling; can drive activin signaling promoting tumor growth and EMT.
- **Interaction nature**: Pathway co-membership with TGF-β superfamily; literature evidence (Europe PMC 41992239) directly links high INHBB to poor CRC prognosis and malignant phenotypes.
- **Evidence**: Direct (input/uploaded HR/FDR) + literature (independent CRC-specific study).

### 2. CDX2 (Protective, HR=0.7478, FDR=0.0355)
- **Statistical direction**: Protective; loss associated with worse survival.
- **Biological role**: Master intestinal transcription factor; suppresses Wnt/β-catenin (PubMed 30631044).
- **Interaction nature**: Regulatory interaction — CDX2 transactivates GSK-3β and Axin2, which are negative regulators of Wnt signaling. This is a documented regulatory relationship, not merely co-expression.
- **Evidence**: Direct (input/uploaded) + literature (mechanistic studies) + clinical (CDX2 loss is an established prognostic marker).

### 3. ZEB1-AS1 (Risk, HR=1.372, FDR=0.008647)
- **Statistical direction**: Risk-associated.
- **Biological role**: Antisense lncRNA to ZEB1; implicated in EMT regulation.
- **Interaction nature**: Putative regulatory interaction with ZEB1 (antisense RNA typically regulates the sense transcript), though direct evidence in this dataset is absent.
- **Evidence**: Direct (input/uploaded) + pathway co-membership (EMT program); specific mechanistic evidence in CRC requires validation.

### 4. Mitochondrial module: ATP23, NDUFA9, ATP5B, CS, COA3, TIMM13 (all protective)
- **Statistical direction**: Consistently protective (HR 0.69–0.75).
- **Biological role**: Oxidative phosphorylation and TCA cycle.
- **Interaction nature**: Pathway co-membership (OXPHOS/TCA); ATP23 has genetic interaction evidence with prohibitins in yeast models (PubMed 17135288). COA3 is a Complex IV assembly factor; TIMM13 is a mitochondrial import protein.
- **Evidence**: Direct (input/uploaded) + pathway/ontology (OXPHOS). This module is notable for its consistency across multiple independent genes.

### 5. DCBLD2 (Risk, HR=1.408, FDR=0.008647)
- **Statistical direction**: Risk-associated (note: ledger indicates direction-conflict across 4 rows; primary row is risk).
- **Biological role**: Transmembrane protein implicated in tumor invasion.
- **Interaction nature**: Indirect/putative within EMT program.
- **Evidence**: Direct (input/uploaded) with caution due to direction-conflict flag.

### 6. AKT3 (Risk, HR=1.318, FDR=0.03875)
- **Statistical direction**: Risk-associated.
- **Biological role**: PI3K/Akt signaling; survival and proliferation.
- **Interaction nature**: Pathway co-membership with PI3K-Akt signaling; 7 rows in ledger indicate multiple probes.
- **Evidence**: Direct (input/uploaded) + pathway (KEGG PI3K-Akt).

### 7. NT5E/CD73 (Risk, HR=1.313, FDR=0.03939)
- **Statistical direction**: Risk-associated.
- **Biological role**: Immunosuppressive ectoenzyme; adenosine production.
- **Interaction nature**: Co-expression/functional relationship with immune evasion programs.
- **Evidence**: Direct (input/uploaded) + literature (PubMed 36480312: pan-cancer prognostic biomarker; immunotherapy relevance).

### 8. LRRC8A (Risk, HR=1.376, FDR=0.02501)
- **Statistical direction**: Risk-associated.
- **Biological role**: Volume-regulated anion channel component; implicated in drug resistance and cell volume regulation.
- **Interaction nature**: Pathway co-membership with cellular stress response.
- **Evidence**: Direct (input/uploaded); limited specific CRC literature in retrieved records.

### 9. MYB (Protective, HR=0.7706, FDR=0.01924)
- **Statistical direction**: Protective.
- **Biological role**: Transcription factor in intestinal homeostasis; STRING shows interactions with CREBBP, EP300, CEBPB (regulatory interactions).
- **Interaction nature**: Regulatory interactions with histone acetyltransferases (CREBBP/EP300) — these are documented protein-protein interactions from STRING, representing regulatory complexes, not just co-expression.
- **Evidence**: Direct (input/uploaded) + protein interaction (STRING).

### 10. TPM4 (Risk, HR=1.364, FDR=0.00891)
- **Statistical direction**: Risk-associated.
- **Biological role**: Tropomyosin 4; actin cytoskeleton dynamics; cell motility.
- **Interaction nature**: Pathway co-membership with cytoskeletal/EMT programs.
- **Evidence**: Direct (input/uploaded); 4 rows in ledger.

## 4. Validation Priorities

### Priority 1: INHBB/activin signaling as a mechanistic driver of poor prognosis
- **Classification**: Mechanistic hypothesis
- **Why**: Strongest statistical signal (HR=1.433, FDR=0.001093); independent literature support in CRC (Europe PMC 41992239).
- **Current dataset evidence**: Single-gene survival association.
- **External evidence**: Published CRC study showing INHBB drives malignant phenotypes; consistent with TGF-β superfamily biology.
- **Next step**: Functional studies (siRNA/shRNA knockdown in CRC cell lines; activin receptor blockade) to test whether INHBB drives proliferation/invasion; assess activin signaling pathway activation in high-INHBB tumors.
- **Conclusion status**: **Supported hypothesis** (statistical association + independent literature; not yet causally validated in this cohort).

### Priority 2: Mitochondrial oxidative metabolism as a protective biomarker module
- **Classification**: Biomarker
- **Why**: Multiple independent mitochondrial genes show consistent protective direction; suggests a coherent metabolic subtype.
- **Current dataset evidence**: 8+ genes with HR < 0.75 (ATP23, NDUFA9, ATP5B, ATP5G1, CS, COA3, TIMM13, OGDHL).
- **External evidence**: Literature supports metabolic heterogeneity in CRC; the retrieved batch did not provide a specific external cohort statistic.
- **Next step**: Validate in an independent CRC cohort (e.g., TCGA-COAD/READ) using a composite mitochondrial score; correlate with metabolic phenotyping (e.g., Seahorse assays on patient-derived organoids).
- **Conclusion status**: **Exploratory hypothesis** (external statistical validation was not performed).

### Priority 3: CDX2 loss as a prognostic biomarker (differentiation axis)
- **Classification**: Biomarker
- **Why**: CDX2 is an established marker; its protective direction here is mechanistically expected.
- **Current dataset evidence**: HR=0.7478, FDR=0.0355.
- **External evidence**: Extensive literature (PubMed 30631044) showing CDX2 suppresses Wnt signaling; CDX2 loss is a known poor-prognosis marker in CRC.
- **Next step**: Immunohistochemistry for CDX2 on the same cohort; assess correlation with survival independent of stage.
- **Conclusion status**: **Established evidence** for CDX2 as a prognostic marker (well-validated in literature); the specific HR in this cohort is a supported finding.

### Priority 4: EMT/stromal signature composition check
- **Classification**: Confounding or composition check
- **Why**: Many risk-associated genes (ZEB1-AS1, TPM4, ITGBL1, DCBLD2, ADAMTS18) are expressed in stromal/cancer-associated fibroblast compartments. The "risk" signal may partly reflect tumor stroma content rather than tumor-cell-intrinsic biology.
- **Current dataset evidence**: Multiple EMT/ECM genes with risk direction.
- **External evidence**: Stromal content is a well-known confounder in bulk tumor transcriptomics.
- **Next step**: Estimate tumor purity (e.g., ESTIMATE, inferCNV); perform cell-type deconvolution (CIBERSORTx); validate key genes by spatial transcriptomics or IHC to localize expression.
- **Conclusion status**: **Exploratory hypothesis** — the EMT signal is real but its cellular origin requires resolution.

### Priority 5: NT5E/CD73 as a potential therapeutic/immunotherapy biomarker
- **Classification**: Therapeutic target (with biomarker component)
- **Why**: CD73 is druggable (anti-CD73 antibodies in clinical development); its risk association suggests potential relevance for immunotherapy stratification.
- **Current dataset evidence**: HR=1.313, FDR=0.03939.
- **External evidence**: PubMed 36480312 supports CD73 as a pan-cancer prognostic and immunotherapy biomarker. Clinical trials targeting CD73 exist (clinicaltrials records retrieved for 32/100 genes), but no CRC-specific efficacy data were retrieved.
- **Next step**: Assess CD73 expression by IHC in the cohort; correlate with immune infiltration (CD8+ T cells); explore whether CD73-high tumors show differential benefit from immunotherapy.
- **Conclusion status**: **Exploratory hypothesis** — the presence of drugs targeting CD73 does not constitute evidence of therapeutic efficacy in CRC.

## 5. Evidence Grounding

**Direct evidence from input/uploaded dataset**: All HR/P/FDR values are direct statistical evidence for this cohort from the uploaded ledger. The strongest direct signals are INHBB, SCARA3, MIR31HG, ATP23, ZEB1-AS1, DCBLD2, NDUFA9, TPM4 (FDR ≤ 0.01).

**Pathway/ontology evidence**: The retrieved GO/KEGG batch returned relatively nonspecific terms (protein binding, cytoplasm, nucleus) and disease-specific KEGG terms (melanoma, gastric cancer) that are not directly applicable to CRC. This is a limitation: the pathway analysis did not independently confirm the EMT/mitochondrial programs inferred from gene-level biology. The Reactome "Fructose catabolism" for GLYCTK and "Glyoxylate and dicarboxylate metabolism" KEGG hit are metabolic annotations consistent with the protective metabolic theme but do not constitute cohort-level enrichment.

**Protein interaction/regulatory evidence**: STRING records provide contextual interactions (e.g., MYB with CREBBP/EP300/CEBPB; GLYCTK with GRHPR/TKFC/ENO1-3; LRCH1/LRCH3 with DOCK6/7/8). These are interaction records, not evidence that these interactions are active in this CRC cohort. The ARG1/ARG2 network connecting ASL and CRYM is consistent with amino acid metabolism.

**Disease-association evidence**: GWAS records were retrieved for 100/100 genes, but the retrieved literature did not identify CRC-specific GWAS hits for the top genes. INHBB has specific CRC literature (Europe PMC 41992239). CDX2 has extensive CRC literature.

**Expression/tissue evidence**: GTEx and HPA records were retrieved for most genes (81/100 and 75/100 respectively). These provide normal-tissue context but do not validate the tumor-specific prognostic association.

**Drug/therapeutic evidence**: ClinicalTrials records for 32/100 genes and ChEMBL for 14/100 genes. NT5E/CD73 has therapeutic relevance. **Important caveat**: drug-target presence does not imply therapeutic efficacy in CRC.

**External/independent validation**: No external/independent cohort validation statistics were available in the supplied external-validation table for the genes highlighted in this interpretation; therefore all statistical claims above refer to the input/uploaded cohort only.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=81, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
